news
Blocking the IL-6 receptor to protect tissues from CRS
The new study’s findings suggest that CRS can be treated with an IL-6 receptor antibody that has a short half-life.
List view / Grid view
The new study’s findings suggest that CRS can be treated with an IL-6 receptor antibody that has a short half-life.
An analysis reveals that in comparison to other inflammatory diseases such as cytokine-release syndrome (CRS) and sepsis, the levels of cytokines in severely ill COVID-19 patients is low.